1. Impact of HTA Therapeutic Reviews on Real World Clinical Practice: The MS Society of Canada’s Perspective Dr. Karen Lee, Vice-President Research

3. www.medicinenet.com

4. Reduce relapse disability Reduce relapse rate Reduce or stop progression Remyelination Neuroprotection 10 therapies approved in Canada with more in the pipeline 0 therapies available

5. Stable A BC MS Population Variability DMT Progressive MS Stable Progressive MS

6. “The unpredictable aspect is paramount since no 2 days are the same and no 2 hours at the same”

7. “ I believe I would be in a wheelchair without this medicine so I continue giving myself an injection once a day until a cure is found”

8. “ I would be interested in trying new drugs if they have minimal side effects and were taken orally rather than injection base.”

9. Views on the Therapeutic Review Assumes all people living with MS are alike, does not take into account the variability in the MS population Restrictive nature of recommendations, does not allow for choice and personalized medicine approach Focused on cost effectiveness versus the person living with MS